MA47541A - Procédé permettant de produire des progéniteurs de lymphocytes t - Google Patents

Procédé permettant de produire des progéniteurs de lymphocytes t

Info

Publication number
MA47541A
MA47541A MA047541A MA47541A MA47541A MA 47541 A MA47541 A MA 47541A MA 047541 A MA047541 A MA 047541A MA 47541 A MA47541 A MA 47541A MA 47541 A MA47541 A MA 47541A
Authority
MA
Morocco
Prior art keywords
producing
lymphocyte progenitors
progenitors
lymphocyte
Prior art date
Application number
MA047541A
Other languages
English (en)
Inventor
Isabelle Andre
Marina Cavazzana
Kuiying Ma
John Tchen
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Inst Nat Sante Rech Med
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Inst Nat Sante Rech Med, Univ Paris Descartes filed Critical Hopitaux Paris Assist Publique
Publication of MA47541A publication Critical patent/MA47541A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MA047541A 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t MA47541A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13

Publications (1)

Publication Number Publication Date
MA47541A true MA47541A (fr) 2019-12-18

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047541A MA47541A (fr) 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t

Country Status (17)

Country Link
US (5) US20200046767A1 (fr)
EP (2) EP4067482A1 (fr)
JP (2) JP7164798B2 (fr)
KR (1) KR102666158B1 (fr)
CN (1) CN110506110B (fr)
AU (1) AU2018217404B2 (fr)
BR (1) BR112019016672A8 (fr)
CA (1) CA3053294A1 (fr)
DK (1) DK3580330T3 (fr)
ES (1) ES2931530T3 (fr)
HU (1) HUE060548T2 (fr)
IL (1) IL268641B2 (fr)
MA (1) MA47541A (fr)
PL (1) PL3580330T3 (fr)
PT (1) PT3580330T (fr)
WO (1) WO2018146297A1 (fr)
ZA (1) ZA201905470B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3077344A1 (fr) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota Procedes de fabrication, d'expansion et d'utilisation d'une cellule t progenitrice humaine
CA3091158A1 (fr) 2018-02-14 2019-08-22 Sunnybrook Research Institute Procede de generation de cellules de la lignee des lymphocytes t
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
EP3963082A4 (fr) * 2019-05-01 2023-01-04 Immunebridge Inc. Procédés de fabrication de précurseurs oligopotents et unipotents
EP3986427A1 (fr) * 2019-06-24 2022-04-27 Childrens Hospital Los Angeles Bcl11bsurexpression depour amélioration de la thymopoïèse et de la fonction des cellules t chez l'humain
JP2023502965A (ja) * 2019-11-14 2023-01-26 ウィリアム ザンドストラ，ピーター 前駆ｔ細胞を製造するための培地処方および方法
JPWO2021200901A1 (fr) * 2020-03-31 2021-10-07
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
AU2022228364A1 (en) * 2021-03-05 2023-09-14 Factor Bioscience Inc. Engineered immune cell therapies
WO2022248354A1 (fr) * 2021-05-25 2022-12-01 Universiteit Gent Génération de précurseurs de lymphocytes t par agonisation du récepteur 2 du facteur de nécrose tumorale
WO2023079082A1 (fr) * 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Méthode de génération de cellules nk
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
JP2026504155A (ja) 2023-01-27 2026-02-03 ノッチ セラピューティクス（カナダ）インコーポレイテッド 幹細胞／前駆細胞からｔ細胞系統集団を生成するための方法
KR20250152088A (ko) * 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (fr) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Procédé de production de progéniteurs de lymphocytes t à partir de cellules souches pluripotentes humaines
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (fr) 1997-12-04 1999-06-10 Duke University Procedes d'isolation et d'utilisation des cellules hematopoietiques cd7+cd34-lin-
WO2009097140A1 (fr) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Procédés d'immunothérapie tumorale prête à l'emploi utilisant des précurseurs de lymphocytes t allogéniques
EP2331679B1 (fr) 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Thérapie cellulaire de tissus ischémiques
AU2009311232B2 (en) * 2008-11-07 2014-10-30 Sunnybrook Health Sciences Centre Human progenitor T-cells
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
CA2795627C (fr) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions et procedes pour fournir une fonction hematopoietique sans correspondance hla
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP2788476B1 (fr) * 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions et procédés pour la génération améliorée de cellules souches/progénitrices hématopoïétiques
WO2014110353A1 (fr) 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Substrats biocompatibles liés à un ligand de notch et leur utilisation dans la formation osseuse
EP3027755B1 (fr) * 2013-08-02 2019-10-09 The Regents of The University of California Modification d'une immunité antivirale médiée par les cellules t par des cellules souches et des récepteurs d'antigène chimériques
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CA2945388A1 (fr) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Recepteurs d'antigenes chimeres (car) utilises dans un traitement et methodes de fabrication associees
CN106062185A (zh) * 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
WO2016039933A1 (fr) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vecteur lentiviral pour le traitement de troubles de l'hémoglobine
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
JP2018518181A (ja) * 2015-06-17 2018-07-12 ザ ユーエービー リサーチ ファンデーション 血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体
WO2017173551A1 (fr) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Procédé de production de cellules t progénitrices à partir de cellules souches et/ou progénitrices et son utilisation
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T

Also Published As

Publication number Publication date
US20210169934A1 (en) 2021-06-10
US20200390817A1 (en) 2020-12-17
IL268641B1 (en) 2024-06-01
IL268641B2 (en) 2024-10-01
PT3580330T (pt) 2022-12-06
KR20190117550A (ko) 2019-10-16
JP7164798B2 (ja) 2022-11-02
KR102666158B1 (ko) 2024-05-16
RU2019125600A3 (fr) 2021-11-03
US20210169935A1 (en) 2021-06-10
EP4067482A1 (fr) 2022-10-05
EP3580330A1 (fr) 2019-12-18
WO2018146297A1 (fr) 2018-08-16
RU2019125600A (ru) 2021-03-15
ZA201905470B (en) 2024-12-18
US11426430B2 (en) 2022-08-30
AU2018217404A2 (en) 2019-09-19
BR112019016672A2 (pt) 2020-04-14
DK3580330T3 (da) 2022-12-05
ES2931530T3 (es) 2022-12-30
JP2020513844A (ja) 2020-05-21
HUE060548T2 (hu) 2023-03-28
BR112019016672A8 (pt) 2022-11-22
CA3053294A1 (fr) 2018-08-16
JP2022185024A (ja) 2022-12-13
PL3580330T3 (pl) 2023-01-16
CN110506110A (zh) 2019-11-26
US11638723B2 (en) 2023-05-02
US20230293586A1 (en) 2023-09-21
CN110506110B (zh) 2024-09-06
EP3580330B1 (fr) 2022-08-31
AU2018217404A1 (en) 2019-09-05
IL268641A (en) 2019-10-31
AU2018217404B2 (en) 2024-03-28
US20200046767A1 (en) 2020-02-13
US11642376B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
MA47541A (fr) Procédé permettant de produire des progéniteurs de lymphocytes t
ZA201901870B (en) Process for producing nonwoven
EP3718462A4 (fr) Procédé de détection
EP3302441A4 (fr) Procédés de production du brivaracetam
SG11201703273SA (en) Process for producing light olefins
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3505540A4 (fr) Procédé de raffinage du sugammadex sodique
SG11201607803QA (en) A draw solute for a forward osmosis process
EP3438272A4 (fr) Procédé de production de xylo-oligosaccharide
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3822259A4 (fr) Procédé de synthèse de valsartan
PL3364800T3 (pl) Sposób wytwarzania zasadniczo cylindrycznych artykułów
EP3764172A4 (fr) Procédé de servocommande
EP3513888A4 (fr) Procédé de coulée continue
EP3458948A4 (fr) Procédé de fourniture de notifications
EP3436571C0 (fr) Procédé de culture de lymphocyte b
SG11201703275TA (en) A process for producing light olefins
EP3424894A4 (fr) Procédé de production de butadiène
EP3564245A4 (fr) Dérivé de naphthobischalcogénadiazole et son procédé de production
EP3444253A4 (fr) Procédé de préparation de ad-35
EP3455210A4 (fr) Procédé de préparation de boscalide
EP3343216A4 (fr) Procédé d'analyse pour mycotoxines
PL3441765T3 (pl) Sposób wykrywania aktywacji bazofilów
GB201501500D0 (en) Apparatus & process
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives